The $400 price target for AMGN has emerged as a closely watched milestone among investors. This round-number level sits above the consensus analyst price target of approximately $356 but remains within the range of Wall Street's most optimistic forecasts, which extend as high as $476 according to MarketWatch data. With shares trading around $366, reaching $400 would represent a gain of roughly 9%—not a moonshot, but enough of a climb to require meaningful catalysts.
Several prominent firms have already set targets near this level. Scotiabank initiated coverage with an Outperform rating and a $385 target, while the high end of analyst estimates from multiple firms reaches $400 to $425. These targets reflect confidence in Amgen's commercial portfolio, but the question remains whether the stock can punch through to new all-time high territory.
Amgen Inc., headquartered in Thousand Oaks, California, is one of the world's largest independent biotechnology companies. Founded in 1980, the company discovers, develops, manufactures, and markets human therapeutics across four major therapeutic areas: oncology, cardiovascular disease, bone health, and inflammatory diseases. Its flagship products include Repatha (cholesterol-lowering), Prolia and Xgeva (bone-strengthening), Tezspire (asthma), and Otezla (inflammatory diseases). The 2023 acquisition of Horizon Therapeutics added Tepezza, a treatment for thyroid eye disease, to its rare-disease portfolio. Amgen also operates a rapidly expanding biosimilars business, which now generates close to $3 billion in annual revenue.
Amgen enters the second half of 2026 with significant momentum. The company posted strong third-quarter 2025 results, with revenue growing 12% year-over-year and volumes climbing 14%. Sixteen products delivered double-digit growth during that period. Biosimilar revenue surged more than 50% year-over-year. The company raised its full-year 2025 revenue guidance to between $35.8 and $36.6 billion, and management has consistently demonstrated confidence by increasing the quarterly dividend for 15 consecutive years—most recently raising it by 6% to $2.52 per share.
The stock's valuation reflects this strength but also embeds high expectations. With a trailing price-to-earnings (P/E) ratio near 25 and a forward P/E around 16.5, Amgen trades at a premium to some large-cap pharmaceutical peers but at a discount relative to higher-growth biotech names. This middle-ground valuation leaves room for multiple expansion if pipeline catalysts materialize.
Several factors could propel AMGN toward $400. First, the commercial portfolio continues firing on multiple cylinders. Repatha's expanded cardiovascular outcomes data strengthens its case with physicians, while Tezspire recently received FDA and European approval as the first biologic add-on therapy for chronic rhinosinusitis with nasal polyps—opening a new addressable market.
Second, the pipeline holds potential catalysts. MariTide, Amgen's investigational obesity and type 2 diabetes therapy, represents a significant opportunity in a weight-loss market projected to exceed $100 billion. Bemarituzumab, a cancer drug, has shown encouraging Phase 3 results. Positive clinical readouts from either program could shift sentiment and drive multiple expansion.
Third, Amgen's manufacturing investments—over $40 billion since 2017, including more than $3 billion planned for U.S. facilities in 2025 alone—create a durable competitive moat that supports both branded and biosimilar margins over the long term.
The path to $400 is not without obstacles. Drug pricing pressure remains a persistent overhang for the entire biopharmaceutical sector. While some policy headwinds that dominated 2025 may ease in 2026, legislative and regulatory risk cannot be dismissed, particularly around Medicare negotiation provisions.
Pipeline execution risk is also concrete. Raymond James recently maintained a Market Perform rating on Amgen, citing disappointing trial results from the OX40 rocatinlimab program. Morgan Stanley trimmed its target to $304, noting that recent earnings beats were boosted by one-time items. Not every clinical program will succeed, and setbacks in key pipeline assets could weigh on sentiment.
Additionally, biosimilar competition cuts both ways. While Amgen's own biosimilars business is thriving, its legacy branded products face looming biosimilar threats that could erode high-margin revenue streams over time.
Wall Street's view on Amgen is constructive but measured. Of 38 analysts tracked by MarketWatch, the average 12-month price target stands around $356, with a median of $355. The recommendation consensus falls in the Overweight to Outperform range. The bull-bear spread is unusually wide—ranging from $200 on the low end to $476 on the high end—reflecting genuine uncertainty about pipeline outcomes and the trajectory of biosimilar competition.
Piper Sandler maintains an Overweight rating with a $342 target. BMO Capital rates the stock Outperform. On the more cautious side, Morgan Stanley and Wells Fargo hold Equal Weight ratings with targets of $304 and $325 respectively. Scotiabank's $385 target stands as one of the most bullish among recent initiations. For Amgen to reach $400, the consensus would need to migrate meaningfully higher, likely driven by tangible pipeline success rather than earnings beats alone.
From a technical perspective, AMGN has established a strong uptrend after bouncing from its 2025 lows near $246. The stock's 2026 year-to-date high of approximately $385—reached earlier this year—now serves as the primary resistance zone before $400 comes into play. A decisive break above $385 would likely open the door to a test of the psychologically significant $400 level.
On the downside, the $340–$345 range has acted as support during recent pullbacks, with stronger support near $316. The 52-week low of roughly $259 from the summer of 2025 represents a distant but important floor. The stock's ability to hold above $340 on any dips would be a constructive signal for bulls eyeing the $400 target.
Traders monitoring whether AMGN can reach $400 may benefit from tools that track changing market conditions in real time. Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously scan thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on technical behavior, market patterns, and AI-driven analysis. These signals help traders identify emerging opportunities, manage existing positions, and stay ahead of shifting trends without manually monitoring every tick. For investors tracking Amgen's approach toward the $400 milestone, AI-generated signals can provide a data-driven layer of insight that complements fundamental research.
The $400 price target for Amgen is ambitious but grounded in realistic scenarios. The company's diversified commercial portfolio, expanding biosimilars franchise, and robust manufacturing investments provide a solid foundation. Pipeline catalysts—particularly MariTide in obesity and bemarituzumab in oncology—could supply the incremental enthusiasm needed to push shares beyond current analyst consensus and toward $400.
However, the path is far from guaranteed. Pipeline setbacks, pricing policy headwinds, and biosimilar erosion of legacy products are genuine risks. The wide dispersion in analyst targets reflects this uncertainty. Investors should monitor upcoming clinical data readouts, quarterly revenue trends, and any shifts in the drug pricing regulatory landscape. A sustained break above the $385 resistance level would be a critical technical signal that $400 is within reach—but reaching it will likely require both flawless commercial execution and at least one meaningful pipeline win.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, AMGN has been loosely correlated with BIIB. These tickers have moved in lockstep 62% of the time. This A.I.-generated data suggests there is some statistical probability that if AMGN jumps, then BIIB could also see price increases.
| Ticker / NAME | Correlation To AMGN | 1D Price Change % | ||
|---|---|---|---|---|
| AMGN | 100% | -1.42% | ||
| BIIB - AMGN | 62% Loosely correlated | -1.40% | ||
| BMY - AMGN | 59% Loosely correlated | +0.38% | ||
| NVS - AMGN | 58% Loosely correlated | +0.67% | ||
| GSK - AMGN | 57% Loosely correlated | -1.91% | ||
| PFE - AMGN | 52% Loosely correlated | -0.36% | ||
More | ||||